Showing results (1721-1730 of 1,823) with videos related to

Sort By:
Pageof 183
Experimental Hematology & Oncology|March 21, 2023
PD-L1+ macrophages are associated with favorable features in primary mediastinal (thymic) large B-cell lymphomaRaphael E Steiner, Edwin R Parra, Francisco Vega, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 29, 2025
A Phase I Trial of Evorpacept, Lenalidomide and Rituximab for Patients with B-cell Non-Hodgkin LymphomaPaolo Strati, Lei Feng, Andrey Tyshevich, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 10, 2025
Biomolecular condensation of ERC1 recruits ATG8 and NBR1 to drive autophagosome formation for plant heat toleranceKa Kit Chung, Kai Ching Law, Ziwei Zhao, et al.
Endocrinology|March 31, 2011
Differential impacts of insulin-like growth factor-binding protein-3 (IGFBP-3) in epithelial IGF-induced lung cancer developmentWoo-Young Kim, Mi-Jung Kim, Hojin Moon, et al.
Clinical Lung Cancer|August 9, 2020
Female Gender Predicts Augmented Immune Infiltration in Lung AdenocarcinomaCarmen Behrens, Pedro Rocha, Edwin R Parra, et al.
Plos One|December 2, 2014
Burden and correlates of geriatric depression in the Uyghur elderly population, observation from Xinjiang, ChinaLei Feng, Ping Li, Chen Lu, et al.
Medicine|December 4, 2015
New Cerebral Microbleeds After Mechanical Thrombectomy for Large-Vessel Occlusion StrokesZhong-Song Shi, Gary R Duckwiler, Reza Jahan, et al.
Leukemia & Lymphoma|August 10, 2017
Phase-I and randomized phase-II trial of panobinostat in combination with ICE (ifosfamide, carboplatin, etoposide) in relapsed or refractory classical Hodgkin lymphomaBei Hu, Anas Younes, Jason R Westin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 3, 2008
Pilot randomized phase II study of celecoxib in oral premalignant lesionsVassiliki A Papadimitrakopoulou, William N William, Andrew J Dannenberg, et al.
British Journal of Haematology|March 29, 2019
Lenalidomide plus rituximab (R2 ) in previously untreated marginal zone lymphoma: subgroup analysis and long-term follow-up of an open-label phase 2 trialMelody R Becnel, Loretta J Nastoupil, Felipe Samaniego, et al.
Pageof 183